Methun Rogozin

Dr. Methun Rogozin


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in Toxins
Verified
Journal Article
Open access
PDF file
NZNatalia Alekseevna Zeninskaya
Natalia Alekseevna Zeninskaya
ARAlena K Riabko
Alena K Riabko
MMMaksim A. Marin
Maksim A. Marin
TKTatyana I. Kombarova
Tatyana I. Kombarova
MSMaria A. Shkuratova
Maria A. Shkuratova
VFVictoria V. Firstova
Victoria V. Firstova
Botulism is one of the most serious food intoxications, manifesting as prolonged paralytic conditions. This disease is usually the result of the consumption of poor quality canned or smoked foods, so the inhabitants of many countries of the world are exposed to the risk of this kind of poisoning every year. In view of the severity of poisonings caused by botulinum neurotoxins, monoclonal antibodies (mAbs) show great promise because of their targeting action, lack of allergic reactions and serum sickness. The use of a cocktail of mAbs increases the “functional specificity” of their mixture, allowing them to bind to the active domains of different toxin chains and block their action. In this work, we obtained 14 murine mAbs to the catalytic and receptor-binding domain of botulinum toxin type A. The Sp2/0-Ag14 murine myeloma cell line and splenocytes from immunized mice of the BALB/c line were used as fusion partners. We have shown that the selected cocktail of three antibodies neutralizes native toxin more effectively than antibodies separately—complete neutralization is achieved at a toxin dose of 3LD50 and partial neutralization at 5LD50. We presume that this cocktail may be promising as a prototype for the creation of a therapeutic drug capable of neutralizing the toxin in the blood of patients.

30 August 2026 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
ILIrina S. Lutcheva
Irina S. Lutcheva
ЛСЛутчева Ирина Сергеевна
Лутчева Ирина Сергеевна
MRMetkhun M. Rogozin
Metkhun M. Rogozin
MRMethun Rogozin
Methun Rogozin
NZNatalia Alekseevna Zeninskaya
Natalia Alekseevna Zeninskaya
ФВФирстова Виктория Валерьевна
Фирстова Виктория Валерьевна
Introducion. Ricin is a glycoprotein phytotoxin that is characterised by high toxicity and relatively simple extraction methods. Monoclonal antibodies (mAbs) against ricin represent a key component in the development of immunodiagnostic test systems and preparations for the specific prevention and treatment of toxin poisoning. The aim of the present study was to obtain and characterise mouse monoclonal antibodies specific to the ricin B subunit. Materials and methods. Monoclonal antibodies were produced using a hybridoma technology, with the recombinant ricin B subunit (RTB) having been used as the antigen for immunising BALB/c mice. Hybridisation was performed by electrofusion, using the Sp2/0-Ag14 myeloma cell line as the partner cells. The stable hybridoma production was then carried out in vivo in mice. The specificity of the obtained mAbs was then assessed by Western blotting against RTB and native ricin. The parameters of the affinity interaction between the obtained antibodies and RTB were determined by surface plasmon resonance. The selection of the optimal antibodies pair for RTB detection was determined using a sandwich-format enzyme-linked immunosorbent assay (ELISA). In order to assess the neutralising activity of the antibodies against ricin, in vitro tests were carried out using the Vero В cell line, and in vivo tests were conducted using a mouse model. Results. Consequently, 13 mAbs specific to RTB and ricin were obtained and characterised. Following a thorough evaluation of the strength of affinity interaction and the selection of optimal antibody combinations for RTB detection, it was determined that four mAbs (RTB-F1-2, RTB-F1-16, RTB-F2-10 and RTB-F5-1) were identified as promising candidates for the purpose of developing diagnostic test systems. mAbs RTB-F1-15, RTB-F1-16, RTB-F2-10 and RTB-F5-1 demonstrated significant neutralising activity in in vitro tests against ricin at a dose of 8 × IC50. Intravenous administration of the mAbs RTB-F2-10 ensured 100% survival of mice following intraperitoneal ricin intoxication at a dose of 3 × LD50. Conclusion. The feasibility of utilising high-affinity mAbs (RTB-F1-2, RTB-F1-16, RTB-F2-10 and RTB-F5-1) for the design of diagnostic test systems has been demonstrated through experimental means. The data obtained on the neutralising properties of the mAb RTB-F2-10 in in vitro and in vivo tests allows it to be considered as a basis for the development of a therapeutic agent using chimerisation and humanisation strategies.